个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

The potent role of Src kinase-regulating glucose metabolism in cancer

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Shao Wenjun[1] * ; Liu Li[1] ; Zheng Fuxiang[2] ; Ma Yanmin[1] ; Zhang Ji[1,2,*1,*2] ;
机构： [1]The First Affiliated Hospital, Department of Clinical Laboratory Medicine, Institution of Microbiology and Infectious Diseases, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, China [2]Department of Clinical Laboratory, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518033, Guangdong, China
出处：
DOI： 10.1016/j.bcp.2022.115333
ISSN：

关键词： Src kinase Glucose metabolism Warburg effect Cancer Targeted therapy

摘要：
Src kinase is a membrane-related nonreceptor tyrosine kinase that plays an essential role in cell growth, division, migration, and survival signaling pathways. In addition, it regulates glucose metabolism in cancer cells through different mechanisms, such as directly regulating glucose metabolism related enzymes and glucose transporters or indirectly regulating transcription factors and signal transduction pathways. In this review, we clarify the role of Src kinase in regulating glucose metabolism in cancer cells, and partially explain the pathogenesis of malignant tumors. We also discuss that further understanding and study of the role of Src kinase in glucose metabolism will provide a potential therapeutic window for cancer treatment.Copyright © 2022 Elsevier Inc. All rights reserved.

基金：
This work was funded by the National Natural Science Foundation of China (No. 82170138, 81870105), Natural Science Foundation of Hunan Province (No. 2021JJ30022), Scientific Research Fund Project of Hunan Provincial Health Commission (No. 20201921).
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2021]版：
大类 | 2 区 医学
小类 | 2 区 药学
最新[2025]版：
大类 | 2 区 医学
小类 | 2 区 药学
JCR分区：
出版当年[2020]版：
Q1 PHARMACOLOGY & PHARMACY
最新[2023]版：
Q1 PHARMACOLOGY & PHARMACY

影响因子： 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者：
第一作者机构： [1]The First Affiliated Hospital, Department of Clinical Laboratory Medicine, Institution of Microbiology and Infectious Diseases, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, China
通讯作者：
通讯机构： [1]The First Affiliated Hospital, Department of Clinical Laboratory Medicine, Institution of Microbiology and Infectious Diseases, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, China [2]Department of Clinical Laboratory, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518033, Guangdong, China [*1]Department of Clinical Laboratory, The First Affiliated Hospital of University of South China, Hengyang, Hunan, PR China [*2]Department of Clinical Laboratory, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, PR China.
推荐引用方式(GB/T 7714)：
Shao Wenjun,Liu Li,Zheng Fuxiang,et al.The potent role of Src kinase-regulating glucose metabolism in cancer[J].BIOCHEMICAL PHARMACOLOGY.2022,206:doi:10.1016/j.bcp.2022.115333.
APA：
Shao Wenjun,Liu Li,Zheng Fuxiang,Ma Yanmin&Zhang Ji.(2022).The potent role of Src kinase-regulating glucose metabolism in cancer.BIOCHEMICAL PHARMACOLOGY,206,
MLA：
Shao Wenjun,et al."The potent role of Src kinase-regulating glucose metabolism in cancer".BIOCHEMICAL PHARMACOLOGY 206.(2022)

相关文献

[1]PRMT5 promotes ovarian cancer growth through enhancing Warburg effect by methylating ENO1 [2]Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer [3]iNOS-derived nitric oxide promotes glycolysis by inducing pyruvate kinase M2 nuclear translocation in ovarian cancer. [4]Developing liver-targeted naringenin nanoparticles for breast cancer endocrine therapy by promoting estrogen metabolism [5]Biotin decorated celastrol-loaded ZIF-8 nano-drug delivery system targeted epithelial ovarian cancer therapy [6]Effect of Cinnamaldehyde on Glucose Metabolism and Vessel Function. [7]Effect of Cinnamaldehyde on Glucose Metabolism and Vessel Function. [8]The miR-1185-2-3p-GOLPH3L pathway promotes glucose metabolism in breast cancer by stabilizing p53-induced SERPINE1. [9]Self-carried nanodrug (SCND-SIS3): A targeted therapy for lung cancer with superior biocompatibility and immune boosting effects [10]Reporting of tumor lysis syndrome with targeted therapy for hepatic cancer in the FDA adverse events reporting system

资源点击量：2018 今日访问量：0 总访问量：645 更新日期：2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持：重庆聚合科技有限公司 地址：广州市越秀区大德路111号